术前乳腺MRI筛选的早期乳腺癌患者术后放疗省略(PROSPECT):前瞻性双臂研究主要结果
PROSPECT是一项在澳大利亚四家学术医院开展的前瞻性、多中心、双臂、非随机试验,评估术前乳腺MRI联合术后病理筛选可安全省略放疗的早期乳腺癌患者。2011年5月17日至2019年5月6日,443例患者接受MRI;201例符合条件的患者接受保乳手术并省略放疗,5年同侧浸润性复发率为1.0%(95%CI上限5.4%)。PROSPECT路径使每例患者质量调整生命年增加0.019(95%CI 0.008-0.029),节省1980澳元(95%CI 1396-2528)。
要点
- 术前乳腺MRI和术后病理可筛选出真正局限的早期乳腺癌患者,安全省略术后放疗。
- 省略放疗组201例患者5年同侧浸润性复发率为1.0%(95%CI上限5.4%)。
- PROSPECT路径增加QALYs并节省费用,但需进一步研究验证。
核心结论
- PROSPECT提示,MRI显示单灶乳腺癌且病理结果良好的女性可以安全地省略放疗。
研究设计与样本
- PROSPECT是一项在澳大利亚四家学术医院开展的前瞻性、多中心、双臂、非随机试验,评估基于术前MRI和术后肿瘤病理筛选患者省略放疗。
- 纳入年龄50岁及以上、cT1N0非三阴性乳腺癌的女性;影像学表现为单灶者接受保乳手术,若病理为pT1N0或N1mi则省略放疗(第1组),其余患者接受标准治疗包括切除MRI检出的额外癌灶(第2组)。
- 主要结局为第1组5年同侧浸润性复发率(IIRR);主要分析在第100例第1组患者随访满5年后进行。
- 研究在澳大利亚新西兰临床试验注册中心注册(ACTRN12610000810011)。
主要发现
- 2011年5月17日至2019年5月6日,443例乳腺癌患者接受MRI,中位年龄63.0岁。
- MRI在48例患者(11%)中检出61个与索引癌灶分离的恶性隐匿病灶。
- 第1组201例接受保乳手术并省略放疗的患者,5年IIRR为1.0%(95%CI上限5.4%);第1组中一例局部复发发生在4.5年,第二例发生在7.5年。
- 第2组中9例患者接受乳房切除术(占全部队列2%),5年IIRR为1.7%(95%CI上限6.1%)。
- 整个队列中唯一的远处转移与索引癌灶在遗传学上不同。
关键数值与推荐
- 第1组201例省略放疗患者5年IIRR为1.0%(95%CI上限5.4%)。
- 第2组5年IIRR为1.7%(95%CI上限6.1%)。
- PROSPECT路径QALYs增加0.019(95%CI 0.008-0.029),每例患者节省1980澳元(95%CI 1396-2528)或953英镑(95%CI 672-1216)。
临床怎么用
- PROSPECT提示,MRI显示单灶乳腺癌且病理结果良好的女性可以安全地省略放疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant breast radiotherapy as a standard component of breast-conserving treatment for early cancer can overtreat many women. Breast MRI is the most sensitive modality to assess local tumour burden. The aim of this study was to determine whether a combination of MRI and pathology findings can identify women with truly localised breast cancer who can safely avoid radiotherapy. METHODS: PROSPECT is a prospective, multicentre, two-arm, non-randomised trial of radiotherapy omission in patients selected using preoperative MRI and postoperative tumour pathology. It is being conducted at four academic hospitals in Australia. Women aged 50 years or older with cT1N0 non-triple-negative breast cancer were eligible. Those with apparently unifocal cancer had breast-conserving surgery (BCS) and, if pT1N0 or N1mi, had radiotherapy omitted (group 1). Standard treatment including excision of MRI-detected additional cancers was offered to the others (group 2). All were recommended systemic therapy. The primary outcome was ipsilateral invasive recurrence rate (IIRR) at 5 years in group 1. Primary analysis occurred after the 100th group 1 patient reached 5 years follow-up. Quality-adjusted life-years (QALYs) and cost-effectiveness of the PROSPECT pathway were analysed. This study is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12610000810011). FINDINGS: Between May 17, 2011, and May 6, 2019, 443 patients with breast cancer underwent MRI. Median age was 63·0 years. MRI detected 61 malignant occult lesions separate from the index cancer in 48 patients (11%). Of 201 group 1 patients who had BCS without radiotherapy, the IIRR at 5 years was 1·0% (upper 95% CI 5·4%). In group 1, one local recurrence occurred at 4·5 years and a second at 7·5 years. In group 2, nine patients had mastectomy (2% of total cohort), and the 5-year IIRR was 1·7% (upper 95% CI 6·1%). The only distant metastasis in the entire cohort was genetically distinct from the index cancer. The PROSPECT pathway increased QALYs by 0·019 (95% CI 0·008-0·029) and saved AU$1980 (95% CI 1396-2528) or £953 (672-1216) per patient. INTERPRETATION: PROSPECT suggests that women with unifocal breast cancer on MRI and favourable pathology can safely omit radiotherapy. FUNDING: Breast Cancer Trials, National Breast Cancer Foundation, Cancer Council Victoria, the Royal Melbourne Hospital Foundation, and the Breast Cancer Research Foundation.
引用
- Mann GB, Skandarajah AR, Zdenkowski N, et al. Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study. Lancet. 2023. PMID: 38065194. doi:10.1016/S0140-6736(23)02476-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。